


LIVER CANCER: BREAKTHROUGHS AND NEW THERAPIES



Friday, November 20, 2026
8:30am to 4:30pm EST

Davis Auditorium
1470 Madison Avenue
New York, NY 10029

[https://mssm.cloud-cme.com/
LiverCancer2026](https://mssm.cloud-cme.com/LiverCancer2026)

Program Director

Josep M. Llovet, MD, PhD

Director, Mount Sinai Liver Cancer Program

Sponsored by

Mount Sinai Liver Cancer Program
Icahn School of Medicine at Mount Sinai

PROGRAM DIRECTOR

JOSEP M. LLOVET, MD, PHD, Director, Mount Sinai Liver Cancer Program, Professor of Medicine, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

PROGRAM CHAIRS

SCOTT L. FRIEDMAN, MD, Dean for Collaborative Research and Partnerships, Fishberg Professor of Medicine, Director, Center for Liver Research, Icahn School of Medicine at Mount Sinai, New York, NY

MYRON SCHWARTZ, MD, The Henry Kaufmann Professor of Surgery, Senior Associate Dean for Human Subjects Research, Icahn School of Medicine at Mount Sinai, New York, NY

PROGRAM COMMITTEE SECRETARY

DANIELA SIA, PHD, Associate Professor, Department of Medicine, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

PROGRAM DESCRIPTION

This conference will assemble multidisciplinary experts on chronic liver diseases, hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) from the Mount Sinai Liver Cancer Program and one outstanding invited lecturer. The meeting aims to provide a summary of the state-of-the-art knowledge of the novel advancements reported in 2025-2026 in the pathogenesis and clinical management of liver cancer, including the research conducted at Mount Sinai. Results of new RCT reported this year that will change clinical practice will be reviewed.

PROGRAM OBJECTIVES

1. Define the molecular pathogenesis and targeted therapies in liver cancer.
2. Discuss the role of surgical and loco-regional therapies for liver cancer.
3. Update the current AASLD proposed standard of management for advanced HCC with new immune combination therapies.

4. Describe cutting-edge research in liver cancer, highlighting new insights into the pathogenesis of the disease and new molecular and immune therapies, conducted at the Mount Sinai Liver Cancer Program 2025-26.

PRIMARY AUDIENCE

Hepatologists, Gastroenterologists, Oncologists, Surgeons, Radiologists, Pathologists and Basic Scientists

ACCREDITATION STATEMENT

The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

The Icahn School of Medicine at Mount Sinai designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

VERIFICATION OF ATTENDANCE

Will be provided to all professionals.

CONFERENCE INFORMATION

For further information email: cme@mssm.edu

ONLINE REGISTRATION

<https://mssm.cloud-cme.com/LiverCancer2026>

SPECIAL NEEDS

Icahn School of Medicine at Mount Sinai is in full compliance with provisions of the Americans with Disabilities Act (ADA) and is accessible for individuals with special needs. If you require any special accommodations, please contact The Page and William Black Post-Graduate School at cme@mssm.edu.

AGENDA

8:30 – 9:00am	Registration	
9:00 – 9:15am	Welcome and Opening	Ramon Parsons, MD, PhD; Meena Bansal, MD, FAASLD
9:15 – 9:40am	Achievements of Mount Sinai Liver Cancer Program 2025 - 2026	Josep M. Llovet, MD, PhD
9:40 – 9:50am	A tribute to Swan Thung: a giant in Liver Cancer Pathology	M. Isabel Fiel, MD, MS, FAASLD
9:50 – 10:20am	Hans Popper lecture	Introduction: Josep M. Llovet, MD, PhD
	20-year perspective of Y90 in the management of HCC: present and future	Riad Salem MD, MBA, FSIR, FCIRSE
10:20 – 10:45am	Coffee Break & Picture-Taking	

CLINICAL MANAGEMENT

MOLECULAR PATHOGENESIS AND DIAGNOSIS OF HCC

Moderator: Scott L. Friedman, MD

10:45 – 11:05am	Immune populations in response/ resistance to therapies in cancer and HCC	Alice O. Kamphorst, PhD
11:05 – 11:25am	Molecular pathogenesis of MASH-HCC and potential role of GLP1 agonists	Scott L. Friedman, MD
11:25 – 11:45pm	Molecular pathology of HCC and iCCA	M. Isabel Fiel, MD, MS, FAASLD
11:45 – 12:05pm	Advances in MRI for early detection of HCC	Bachir Taouli, MD, MHA
12:05 – 12:30pm	Lunch Break	

MANAGEMENT OF EARLY –INTERMEDIATE HCC

Moderator: Myron Schwartz, MD

12:30 – 12:50pm	Neoadjuvant approaches in HCC	Tom Marron, MD, PhD
12:50 – 1:10pm	Resection/liver transplantation vs local therapies (Y90, RFA, SBRT) in early HCC	Myron Schwartz, MD
1:10 – 1:30pm	Role of TARE in the management of HCC	Edward Kim, MD, FSIR

MANAGEMENT AND NEW TARGETS IN ADVANCED HCC and CCA

Moderator: Josep M. Llovet, MD, PhD

1:30 – 1:50pm	Overview data on immune therapies for intermediate /advanced HCC	Josep M. Llovet, MD, PhD
1:50 – 2:10pm	Second line therapies in advanced HCC	Dan Feng, MD
2:10 – 2:30pm	Cholangiocarcinoma: KRAS and HER2 inhibitors	Daniela Sia, PhD
2:30 – 2:50pm	Coffee Break	

SHORT COMMUNICATIONS

FLASH COMMUNICATIONS - CLINICAL

Moderator: Augusto Villanueva, MD, PhD

2:50 – 3:00pm	What's new in immunotherapies prior to liver transplantation for HCC?	Parissa Tabrizian, MD
3:00 – 3:10pm	What's new in surveillance tools for HCC?	Tae Hoon Lee, MD
3:10 – 3:20pm	SBRT in early HCC: Is there any role?	Michael Buckstein, MD, PhD
3:20 – 3:30pm	Discussion	

FLASH COMMUNICATIONS - BASIC/TRANSLATIONAL

Moderator: Ernesto Guccione, PhD

3:30 – 3:40pm	Anthony Lozano, PhD	(group of Josep M. Llovet)
3:40 – 3:45pm	Alexandra Wolf, PhD	(group of Daniela Sia)
3:45 – 3:50pm	Guillem Cano	(group of Josep M. Llovet)
3:50 – 3:55pm	Selena Ding	(group of Scott Friedman)
3:55 – 4:00pm	Daniel Vaz	(group of Scott Friedman)
4:00 – 4:05pm	Nataliya Prokhnevskaya, PhD	(group of Alice Kamphorst)
4:05 – 4:10pm	Elisa Arceci	(group of Ernesto Guccione)
4:10 – 4:20pm	Discussion	
4:20 – 4:30pm	Closing Remarks	Josep M. Llovet, MD, PhD

PROGRAM DIRECTOR

JOSEPH M. LLOVET, MD, PhD, Director Mount Sinai Liver Cancer Program, Professor of Medicine, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

PROGRAM CHAIRS

SCOTT L. FRIEDMAN, MD, Dean for Collaborative Research and Partnerships, Fishberg Professor of Medicine Director, Center for Liver Research, Icahn School of Medicine at Mount Sinai, New York, NY

MYRON SCHWARTZ, MD, The Henry Kaufmann Professor of Surgery, Senior Associate Dean for Human Subjects Research, Icahn School of Medicine at Mount Sinai, New York, NY

PROGRAM COMMITTEE SECRETARY

DANIELA SIA, PhD, Associate Professor, Department of Medicine, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

GUEST FACULTY

RIAD SALEM, MD, MBA, FSIR, FCIRSE, Professor of Radiology, Medicine and Surgery, System Vice-Chair, Image-Guided Therapy, Department of Radiology, Northwestern University, Evanston, IL

AUGUSTO VILLANUEVA, MD, PhD, Professor of Medicine, Medical Director, Liver Cancer Program, Division of Gastroenterology and Hepatology, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI FACULTY

MEENA BANSAL, MD, FAASLD, Professor of Medicine, System Chief, Division of Liver Diseases, Director, MASLD/MASH Center of Excellence, Icahn School of Medicine at Mount Sinai, New York, NY

MICHAEL BUCKSTEIN, MD, PhD, Professor and Vice-Chair for Education, Residency Program Director, Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY

DAN FENG, MD, Assistant Professor of Medicine, Gastrointestinal Oncology | Early Phase Trials Unit, Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, NY

M. ISABEL FIEL, MD, MS, FAASLD, Professor and Vice-Chair, Dept. of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY

ERNESTO GUCCIONE, PhD, Mount Sinai Endowed Professor in Epigenetic Therapeutics, Professor, Departments of Oncological Sciences, Immunology & Immunotherapy and Pharmacological Sciences, Director Mount Sinai Center for OncoGenomics and Innovative Therapeutics (COGIT), Icahn School of Medicine at Mount Sinai, New York, NY

ALICE O. KAMPHORST, PhD, Associate Professor of Oncological Sciences, Precision Immunology Institute

EDWARD KIM, MD, FSIR, Professor of Radiology and Surgery, Director, Interventional Oncology, Icahn School of Medicine at Mount Sinai, New York, NY

TAE HOON LEE, MD, Associate Professor, Director of Liver Cancer Screening and Biomarker Discovery Program, Division of Liver Diseases, Mount Sinai Health System, Icahn School of Medicine at Mount Sinai, New York, NY

THOMAS U. MARRON, MD, PHD, Director, Early Phase Trials Unit, Associate Director for Translational Research, Tisch Cancer Center, Professor of Medicine, Hematology & Oncology, Professor of Immunology & Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY

RAMON PARSONS, MD, PhD, Director, Tisch Cancer Institute, Ward-Coleman Chair in Cancer Research, Director, Mount Sinai Cancer, Mount Sinai Health System Chair, Department of Oncological Sciences

PARISSA TABRIZIAN, MD, Professor of Surgery, Recanati/Miller Transplantation Institute, Mount Sinai Liver Cancer Program, Department of Liver Surgery, Icahn School of Medicine at Mount Sinai, New York, NY

BACHIR TAOULI, MD, MHA, Professor of Radiology, Director of Body MRI and Cancer Imaging Program, Vice-chair of Translational Research, Department of Diagnostic, Molecular and Interventional Radiology, BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY

PLANNING COMMITTEE

ELISA FERNANDEZ, BSC, MSC

CASE PRESENTERS

ANTHONY LOZANO, PhD; ALEXANDRA WOLF, PhD; GUILLEM CANO; SELENA DING; DANIEL VAZ; NATALIYA PROKHNEVSKA, PhD; ELISA ARCECI

Faculty Disclosure Policy

It is the policy of the Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all accredited CE educational activities. All individuals in control of content of an activity accredited by ISMMS are expected to disclose all their financial relationships with ineligible companies existing within the prior 24 months. Relevant financial relationships are mitigated and disclosed to learners before the activity takes place. All relevant financial relationships have been mitigated.

LIVER CANCER: BREAKTHROUGHS AND NEW THERAPIES

**FRIDAY, NOVEMBER 20, 2026
8:30am to 4:30pm EST**

Davis Auditorium
1470 Madison Avenue
New York, NY 10029

Sponsored by
Mount Sinai Liver Cancer Program
Icahn School of Medicine at Mount Sinai

Registration Fees

Physicians	\$50.00
Industry Representatives	\$100.00
Allied Health Professionals	\$50.00
Trainees, Students, Residents, Postdocs, Fellows	\$25.00
Mount Sinai Health System	Complimentary

Register Online:

<https://mssm.cloud-cme.com/LiverCancer2026>

Cancellation Policy

All refund and cancellation requests must be emailed to the CME office at cme@mssm.edu by Friday, November 13, 2026. Cancellations after this date are not eligible for a refund. An administrative fee of \$50 will be deducted from your refund. No refunds will be issued for registration fees that are equal to or less than \$50.

For conference information please email the Office of CME at cme@mssm.edu